Camp4 Therapeutics Corp CAMP
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $4.09
- Day Range
- $4.09–4.44
- 52-Week Range
- $1.31–7.75
- Bid/Ask
- $4.04 / $4.27
- Shares Outstanding
- 51.93M
- Market Cap
- $219.91M
- Volume/Avg
- 3,145 / 97,584
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 41.40
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Camp4 Therapeutics Corp is a clinical-stage biopharmaceutical company pioneering the discovery and development of regulatory RNA-based therapeutics to upregulate gene expression and restore healthy protein levels to treat various genetic diseases. The company focuses on genetic diseases of the central nervous system and liver. Its pipeline products include CMP-CPS-001 and CMP-SYNGAP. The company operates as a single operating segment, R&D, which engages in the development of a new class of RNA-based therapeutics to treat a broad range of genetic diseases.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 48
- Website
- https://www.camp4tx.com
Valuation
|
Metric
|
CAMP
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 6.87 |
Price/Sales | 41.40 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
CAMP
|
|---|---|
Quick Ratio | 5.97 |
Current Ratio | 6.15 |
Interest Coverage | — |
Quick Ratio
CAMP
Profitability
|
Metric
|
CAMP
|
|---|---|
Return on Assets (Normalized) | −95.82% |
Return on Equity (Normalized) | −177.42% |
Return on Invested Capital (Normalized) | −164.58% |
Return on Assets
CAMP
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| Htgqbswgm | Jynkhsz | $112B | |||
| Regeneron Pharmaceuticals Inc
REGN
| Twgszhyv | Ltjymr | $64B | |||
| argenx SE ADR
ARGX
| Zvwwbvfd | Fdlh | $55B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Bhssgmjm | Vsgylb | $39B | |||
| Royalty Pharma PLC Class A
RPRX
| Ltktmhnsw | Rzhpl | $24B | |||
| BioNTech SE ADR
BNTX
| Xmszhkmt | Nztx | $22B | |||
| Incyte Corp
INCY
| Svrbtfsv | Fcj | $20B | |||
| Moderna Inc
MRNA
| Zbzglcbnn | Shw | $19B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| Mcddhnpk | Jvvq | $15B | |||
| BridgeBio Pharma Inc
BBIO
| Xnvkrwnjx | Qwz | $13B |
United States